Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas

被引:95
作者
Camilo, R [1 ]
Capelozzi, VL [1 ]
Siqueira, SAC [1 ]
Del Carlo Bernardi, F [1 ]
机构
[1] Univ Sao Paulo, Sch Med, Dept Pathol, BR-01246903 Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
non-small cell carcinoma of the lung; immunohistochemical; p63; CK5/CK6; CK7 and surfactant-A;
D O I
10.1016/j.humpath.2005.12.019
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
In this study, we sought to validate the importance of p63, CK5/CK6, CK7, and surfactant-A (SP-A) to classify 42 non-small cell lung cancers in autopsy and surgical resection specimens and to study the usefulness of these markers in distinguishing between squamous cell carcinomas and adenocarcinomas because of their different implications regarding treatment and prognosis. All adenocarcinoma cases were negative for p63; 9 (56.2%) of 16 were CK5/CK6 positive, 16 (94.1%) of 17 were CK7 positive, and 4 (26.6%) of 15 were SP-A positive. In squamous cell carcinoma, I case was CK7 and SP-A positive and 14 (77.8%) of 18 were p63 positive. The latter appears to be useful in differentiating squamous cell carcinoma from adenocarcinoma of the lung in small biopsies without keratinization or glandular differentiation; thus, for advanced-stage cases, where there is no possibility of surgical resection and the treatment of choice is radiotherapy plus chemotherapy, we would be able to differentiate between the two histological types, establishing then a different therapy. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:542 / 546
页数:5
相关论文
共 25 条
[1]  
[Anonymous], 1991, Respiratory Disease in Practice
[2]   Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma - A study with logistic regression analysis [J].
Carella, R ;
Deleonardi, G ;
D'Errico, A ;
Salerno, A ;
Egarter-Vigl, E ;
Seebacher, C ;
Donazzan, G ;
Grigioni, WF .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (01) :43-50
[3]   Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].
Fukuoka, M ;
Yano, S ;
Giaccone, G ;
Tamura, T ;
Nakagawa, K ;
Douillard, JY ;
Nishiwaki, Y ;
Vansteenkiste, J ;
Kudoh, S ;
Rischin, D ;
Eek, R ;
Horai, T ;
Noda, K ;
Takata, I ;
Smit, E ;
Averbuch, S ;
Macleod, A ;
Feyereislova, A ;
Dong, RP ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246
[4]   Lung cancer [J].
Hoffman, PC ;
Mauer, AM ;
Vokes, EE .
LANCET, 2000, 355 (9202) :479-485
[5]   Lung cancer [J].
Iannettoni, MD ;
Lynch, WR .
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 20 (05) :405-418
[6]  
Johansson Leif, 2004, Ann Diagn Pathol, V8, P259, DOI 10.1016/j.anndiagpath.2004.07.001
[7]  
Kaufmann O, 2001, AM J CLIN PATHOL, V116, P823
[8]   Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial [J].
Kris, MG ;
Natale, RB ;
Herbst, RS ;
Lynch, TJ ;
Prager, D ;
Belani, CP ;
Schiller, JH ;
Kelly, K ;
Spiridonidis, H ;
Sandler, A ;
Albain, KS ;
Cella, D ;
Wolf, MK ;
Averbuch, SD ;
Ochs, JJ ;
Kay, AC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16) :2149-2158
[9]   Microtubule-associated protein-2: A new sensitive and specific marker for pulmonary carcinoid tumor and small cell carcinoma [J].
Liu, YL ;
Sturgis, CD ;
Grzybicki, DM ;
Jasnosz, KM ;
Olson, PR ;
Tong, M ;
Dabbs, DD ;
Raab, SS ;
Silverman, JF .
MODERN PATHOLOGY, 2001, 14 (09) :880-885
[10]   Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas [J].
Lyda, MH ;
Weiss, LM .
HUMAN PATHOLOGY, 2000, 31 (08) :980-987